Giurgea's five criteria for nootropics (learning/memory enhancement, resistance to disruption, neuroprotection, support of higher integrative mechanisms, low toxicity)
Its potential for faster joint recovery , reduced injury downtime , and enhanced off-cycle repair makes it an attractive option in the recovery arsenal
Its primary mechanisms of action center on tissue regeneration, anti-inflammatory signaling, and angiogenesis the formation of new blood vessels
PMID: 15655171
Each 10 units on the syringe equals 1 mg
The WHO estimates it affects between 1020% of people infected with SARS-CoV-2 tens of millions globally.1 The symptoms are wide-ranging but cluster into recognizable patterns: Neurological: brain fog, cognitive impairment, headaches, sleep disruption Cardiovascular: chest pain, breathlessness, tachycardia (POTS), reduced exercise tolerance Immune: persistent low-grade inflammation, recurrent infections, autoimmune flares Musculoskeletal: post-exertional malaise (PEM), joint pain, muscle weakness Metabolic/endocrine: insulin dysregulation, thyroid disruption, adrenal fatigue signals Standard care rest, symptom management, antidepressants, rehabilitation programs helps some patients
